Project Grant R01HL178795
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $824K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded Case Western Reserve University $1,573,126 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an artificial intelligence-based decision-support tool that identifies patients at risk of myocardial ischemia using low-cost or no-cost screening data. The tool will analyze CT calcium scores, electrocardiogram data, and clinical risk factors to serve as a gatekeeper strategy for determining which patients...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $109,076 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop improved cardiovascular risk prediction models using advanced computational methods applied to cardiac CT imaging. The research applies deep learning to detect small, low-density calcifications on coronary artery calcium score exams that are predictive of early-stage atherosclerosis and near-term...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $431,750 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cell-free hemoglobin and red blood cell-derived extracellular vesicles as contributors to immune dysregulation and cardiovascular disease risk in people with HIV. The award funds research into the hypothesis that extracellular vesicles containing cell-free hemoglobin trigger endothelial dysfunction and...
- The National Heart, Lung, and Blood Institute awarded the University of Utah $231,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a meta-analysis of randomized controlled trials evaluating decision aids for stroke prevention in atrial fibrillation. The research synthesizes patient-level data from three large randomized controlled trials to quantify the overall effectiveness of decision aids on patient-centered and clinical outcomes,...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $830,260 on July 16, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to implement shared decision-making for pediatric sickle cell disease treatment selection. The project, titled "Implementation of Shared Decision-Making for Sickle Cell Disease (IMPLEMENT-SDM Study)," develops and disseminates a shared decision-making toolkit designed to integrate medical evidence...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University, Office of Research Administration $1,532,398 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a gene therapy delivery platform for cardiomyopathies. The project, titled "Bait and Switch Gene Therapy for Cardiomyopathies," addresses the clinical translation barrier in adeno-associated virus (AAV) gene therapy for genetic heart diseases including...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $4,349,952 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the phosphorylation-based molecular and functional mechanisms by which cardiac myosin binding protein C (CMYBP-C) modulates cardiac contractile function. The research employs a multidisciplinary experimental approach spanning atomic to whole-organ scales to determine how CMYBP-C conformational changes in...
- The National Heart, Lung, and Blood Institute awarded the University of Massachusetts Medical School $858,456 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Assistance Listing R01HL184047) to develop and test an interoperable shared decision-making tool integrated into electronic health records for stroke prevention in atrial fibrillation patients. The project, titled DECIDE-AF, addresses suboptimal anticoagulation initiation and persistence among AF...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $729,984 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 22, 2026. The award funds development of a three-dimensional real-time cardiovascular magnetic resonance imaging (3D RT CMR) reconstruction framework for imaging patients with cardiac arrhythmias. The proposed unsupervised reconstruction method, called Generative Prior with Multi-Dynamic Modeling (GEMM), enables highly accelerated 3D RT...
- The National Heart, Lung, and Blood Institute (NHLBI) within the National Institutes of Health awarded The Ohio State University $121,658 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how inflamed adipose tissue modulates vascular inflammation through adipocyte-derived extracellular vesicles. The funded research decodes the role of adipocyte-derived extracellular vesicle cargo in promoting cardiovascular disease risk in obese populations. The...